Long‐term efficacy and safety of oxycodone‐naloxone prolonged‐release formulation (up to 180/90 mg daily) – results of the open‐label extension phase of a phase III multicenter, multiple‐dose, randomized, controlled study

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles